Medivation Inc (MDVN) 60.01 $MDVN
Medivation Has Returned 48.2% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Fri Jun 10, 12:21AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 48.23% as of today's recent price of $60.10.
MDVN: 60.01 (-0.09)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 60.01 (-0.09), ACAD: 39.60 (-0.61), OPK: 9.30 (-0.31), CLDX: 4.12 (-0.20)
Uptrend Call Working As Medivation Stock Rises 49.5% (MDVN)
Comtex SmarTrend(R) - Thu Jun 02, 12:45PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 2 months, Medivation has returned 49.48% as of today's recent price of $60.61.
MDVN: 60.01 (-0.09)
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Marketwired - Thu Jun 02, 6:00AM CDT
SAN FRANCISCO, CA and TOKYO, JAPAN--(Marketwired - June 02, 2016) - Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 60.01 (-0.09)
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 60.01 (-0.09)
Medivation Sets Record Date for Sanofi's Proposed Consent Solicitation
BusinessWire - Wed Jun 01, 5:45PM CDT
Medivation, Inc. (NASDAQ:MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company's stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi (the "Sanofi Consent Solicitation"
. In accordance with that request, the Company's Board of Directors has set the close of business on June 1, 2016 as the record date for the Sanofi Consent Solicitation.
MDVN: 60.01 (-0.09)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Medivation Files Preliminary Consent Revocation Statement
BusinessWire - Fri May 27, 7:08AM CDT
--Hostile Consent Solicitation Merely a Tactic to Facilitate Sanofi's Substantially Inadequate Proposal;Hand-Picked Nominees Have Minimal Biotech Experience
MDVN: 60.01 (-0.09)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 60.01 (-0.09), NVO: 55.36 (-1.51), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
Uptrend Call Working As Medivation Stock Rises 51.6% (MDVN)
Comtex SmarTrend(R) - Thu May 26, 12:10AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 2 months, Medivation has returned 51.63% as of today's recent price of $61.48.
MDVN: 60.01 (-0.09)
Medivation to Present at the Following Conferences
Marketwire Canada - Wed May 25, 3:10PM CDT
SAN FRANCISCO, CA--(Marketwired - May 25, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced participation at the following investor conferences:
MDVN: 60.01 (-0.09)
Sanofi wants to dump Medivation's board after rejected deal
AP - Wed May 25, 10:00AM CDT
NEW YORK (AP) — French drug company Sanofi is trying to toss the entire board at Medivation after the U.S. drugmaker rejected its $9.3 billion takeover bid.
MDVN: 60.01 (-0.09)
Medivation Urges Stockholders to Reject Sanofi's Attempt to Replace Medivation Board of Directors
BusinessWire - Wed May 25, 7:46AM CDT
--Medivation to Promptly File Consent Revocation Materials
MDVN: 60.01 (-0.09)
Arm of I-SPY 2 TRIAL Investigating Medivation's Talazoparib for Treatment of Breast Cancer Activated
Marketwire Canada - Mon May 23, 6:00AM CDT
Talazoparib Investigated in Neoadjuvant Setting in Patients With Newly Diagnosed, Locally Advanced Breast Cancer
MDVN: 60.01 (-0.09)
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 60.01 (-0.09), TTPH: 3.94 (-0.17), TRVN: 6.84 (-0.38), ADRO: 11.99 (-0.43), ANAC: 99.17 (+0.09)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 60.01 (-0.09), TRVN: 6.84 (-0.38), TTPH: 3.94 (-0.17), VRTX: 91.49 (-1.00), ADRO: 11.99 (-0.43), AMGN: 154.78 (-2.00), ANAC: 99.17 (+0.09)
Medivation Has Returned 48.2% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Fri Jun 10, 12:21AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 48.23% as of today's recent price of $60.10.
MDVN: 60.01 (-0.09)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 60.01 (-0.09), ACAD: 39.60 (-0.61), OPK: 9.30 (-0.31), CLDX: 4.12 (-0.20)
Uptrend Call Working As Medivation Stock Rises 49.5% (MDVN)
Comtex SmarTrend(R) - Thu Jun 02, 12:45PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 2 months, Medivation has returned 49.48% as of today's recent price of $60.61.
MDVN: 60.01 (-0.09)
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Marketwired - Thu Jun 02, 6:00AM CDT
SAN FRANCISCO, CA and TOKYO, JAPAN--(Marketwired - June 02, 2016) - Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 60.01 (-0.09)
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 60.01 (-0.09)
Medivation Sets Record Date for Sanofi's Proposed Consent Solicitation
BusinessWire - Wed Jun 01, 5:45PM CDT
Medivation, Inc. (NASDAQ:MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company's stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi (the "Sanofi Consent Solicitation"
. In accordance with that request, the Company's Board of Directors has set the close of business on June 1, 2016 as the record date for the Sanofi Consent Solicitation. MDVN: 60.01 (-0.09)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Medivation Files Preliminary Consent Revocation Statement
BusinessWire - Fri May 27, 7:08AM CDT
--Hostile Consent Solicitation Merely a Tactic to Facilitate Sanofi's Substantially Inadequate Proposal;Hand-Picked Nominees Have Minimal Biotech Experience
MDVN: 60.01 (-0.09)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 60.01 (-0.09), NVO: 55.36 (-1.51), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
Uptrend Call Working As Medivation Stock Rises 51.6% (MDVN)
Comtex SmarTrend(R) - Thu May 26, 12:10AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 2 months, Medivation has returned 51.63% as of today's recent price of $61.48.
MDVN: 60.01 (-0.09)
Medivation to Present at the Following Conferences
Marketwire Canada - Wed May 25, 3:10PM CDT
SAN FRANCISCO, CA--(Marketwired - May 25, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced participation at the following investor conferences:
MDVN: 60.01 (-0.09)
Sanofi wants to dump Medivation's board after rejected deal
AP - Wed May 25, 10:00AM CDT
NEW YORK (AP) — French drug company Sanofi is trying to toss the entire board at Medivation after the U.S. drugmaker rejected its $9.3 billion takeover bid.
MDVN: 60.01 (-0.09)
Medivation Urges Stockholders to Reject Sanofi's Attempt to Replace Medivation Board of Directors
BusinessWire - Wed May 25, 7:46AM CDT
--Medivation to Promptly File Consent Revocation Materials
MDVN: 60.01 (-0.09)
Arm of I-SPY 2 TRIAL Investigating Medivation's Talazoparib for Treatment of Breast Cancer Activated
Marketwire Canada - Mon May 23, 6:00AM CDT
Talazoparib Investigated in Neoadjuvant Setting in Patients With Newly Diagnosed, Locally Advanced Breast Cancer
MDVN: 60.01 (-0.09)
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 60.01 (-0.09), TTPH: 3.94 (-0.17), TRVN: 6.84 (-0.38), ADRO: 11.99 (-0.43), ANAC: 99.17 (+0.09)
Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 60.01 (-0.09), TRVN: 6.84 (-0.38), TTPH: 3.94 (-0.17), VRTX: 91.49 (-1.00), ADRO: 11.99 (-0.43), AMGN: 154.78 (-2.00), ANAC: 99.17 (+0.09)
